Skip to content

ANEBULO PHARMACEUTICALS, INC.: 10-Q filed 2024-05-15

What ANEBULO PHARMACEUTICALS, INC. reported in its quarterly report filed 2024-05-15 (fiscal Q3 2024): 28 published measures, 88 facts as tagged in accession 0001493152-24-019922.

This filing

Form
10-Q (quarterly report)
Filed
2024-05-15
Fiscal period
fiscal Q3 2024
Accession
0001493152-24-019922 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ANEBULO PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2024-03-315,995,635USD
At 2023-06-3011,670,151USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2024-03-311,010,321USD
At 2023-06-301,068,801USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2024-03-314,985,314USD
At 2023-12-316,487,217USD
At 2023-09-308,331,324USD
At 2023-06-3010,601,350USD
At 2023-03-3112,941,521USD
At 2022-12-3115,515,855USD
At 2022-09-3019,117,186USD
At 2022-06-3015,066,900USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2024-03-315,147,139USD
At 2023-06-3011,247,403USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2024-01-01 to 2024-03-31-1,653,542USD91
2023-07-01 to 2024-03-31-6,851,734USD275
2023-10-01 to 2023-12-31-2,717,369USD92
2023-07-01 to 2023-09-30-2,480,823USD92
2023-01-01 to 2023-03-31-2,797,971USD90
2022-07-01 to 2023-03-31-9,236,758USD274
2022-10-01 to 2022-12-31-3,826,952USD92
2022-07-01 to 2022-09-30-2,611,835USD92

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2023-07-01 to 2024-03-31-6,037,910USD275
2022-07-01 to 2023-03-31-6,833,887USD274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2023-07-01 to 2024-03-31-62,354USD275
2022-07-01 to 2023-03-316,450,221USD274

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2024-03-31-64,053,775USD
At 2023-06-30-57,202,041USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2024-01-01 to 2024-03-3125,933,217shares91
2023-07-01 to 2024-03-3125,784,853shares275
2023-01-01 to 2023-03-3125,633,217shares90
2022-07-01 to 2023-03-3124,888,916shares274

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2024-01-01 to 2024-03-3125,933,217shares91
2023-07-01 to 2024-03-3125,784,853shares275
2023-01-01 to 2023-03-3125,633,217shares90
2022-07-01 to 2023-03-3124,888,916shares274

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2024-01-01 to 2024-03-31-0.06USD/shares91
2023-07-01 to 2024-03-31-0.27USD/shares275
2023-01-01 to 2023-03-31-0.11USD/shares90
2022-07-01 to 2023-03-31-0.37USD/shares274

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2024-01-01 to 2024-03-31-0.06USD/shares91
2023-07-01 to 2024-03-31-0.27USD/shares275
2023-01-01 to 2023-03-31-0.11USD/shares90
2022-07-01 to 2023-03-31-0.37USD/shares274

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2024-01-01 to 2024-03-31200,000USD91
2023-07-01 to 2024-03-31581,698USD275
2023-01-01 to 2023-03-31200,000USD90
2022-07-01 to 2023-03-31661,158USD274

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2024-01-01 to 2024-03-31-1,664,251USD91
2023-07-01 to 2024-03-31-6,968,388USD275
2023-01-01 to 2023-03-31-2,864,041USD90
2022-07-01 to 2023-03-31-9,289,210USD274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2024-03-315,370,815USD
At 2023-06-3011,670,151USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2024-01-01 to 2024-03-3159,696USD91
2023-07-01 to 2024-03-3191,534USD275

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2024-03-31384,920USD
At 2023-06-30534,545USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2024-01-01 to 2024-03-311,664,251USD91
2023-07-01 to 2024-03-316,968,388USD275
2023-01-01 to 2023-03-312,864,041USD90
2022-07-01 to 2023-03-319,289,210USD274

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2024-01-01 to 2024-03-31748,339USD91
2023-07-01 to 2024-03-313,081,231USD275
2023-01-01 to 2023-03-311,089,342USD90
2022-07-01 to 2023-03-314,183,038USD274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2024-03-3125,933,217shares
At 2023-06-3025,633,217shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2024-03-3169,013,155USD
At 2023-06-3067,777,757USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2024-03-31624,820USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2024-03-31625,401USD
At 2023-06-30534,256USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2024-01-01 to 2024-03-31915,912USD91
2023-07-01 to 2024-03-313,887,157USD275
2023-01-01 to 2023-03-311,774,699USD90
2022-07-01 to 2023-03-315,106,172USD274

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2024-01-01 to 2024-03-312,321USD91
2023-07-01 to 2024-03-319,384USD275
2023-01-01 to 2023-03-31-13,082USD90
2022-07-01 to 2023-03-31-39,949USD274

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2024-01-01 to 2024-03-3110,709USD91
2023-07-01 to 2024-03-31116,654USD275
2023-01-01 to 2023-03-3166,070USD90
2022-07-01 to 2023-03-3152,452USD274

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2022-07-01 to 2023-03-316,646,748USD274

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2023-07-01 to 2024-03-31-149,625USD275
2022-07-01 to 2023-03-31190,074USD274

Inspect the source

Entity
ANEBULO PHARMACEUTICALS, INC. / CIK 0001815974
Captured
2026-09-21T17:28:29.433Z
SEC response SHA-256
9b7fbc7aa6627d1ba25b78b2b6216133888564e8abee26c007f1576dedf9e9dd

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001815974.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))